Opthea Performance
| OPTDelisted Stock | USD 3.41 0.07 2.01% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Opthea are completely uncorrelated. Opthea right now holds a risk of 0.0%. Please check Opthea accumulation distribution , to decide if Opthea will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Opthea has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Opthea is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Opthea |
Opthea Relative Risk vs. Return Landscape
If you would invest 341.00 in Opthea on October 17, 2025 and sell it today you would earn a total of 0.00 from holding Opthea or generate 0.0% return on investment over 90 days. Opthea is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than Opthea, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Opthea Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opthea's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Opthea, and traders can use it to determine the average amount a Opthea's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| OPT |
Based on monthly moving average Opthea is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Opthea by adding Opthea to a well-diversified portfolio.
Opthea Fundamentals Growth
Opthea Stock prices reflect investors' perceptions of the future prospects and financial health of Opthea, and Opthea fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Opthea Stock performance.
| Return On Equity | -33.83 | |||
| Return On Asset | -0.73 | |||
| Operating Margin | (571.23) % | |||
| Current Valuation | 492.14 M | |||
| Shares Outstanding | 153.91 M | |||
| Price To Book | 4.31 X | |||
| Price To Sales | 2,513 X | |||
| Revenue | 124.67 K | |||
| EBITDA | (200.02 M) | |||
| Cash And Equivalents | 44.63 M | |||
| Cash Per Share | 1.01 X | |||
| Total Debt | 141.65 M | |||
| Book Value Per Share | (0.14) X | |||
| Cash Flow From Operations | (161.02 M) | |||
| Earnings Per Share | (2.25) X | |||
| Total Asset | 188.79 M | |||
| Retained Earnings | (579.7 M) | |||
About Opthea Performance
Assessing Opthea's fundamental ratios provides investors with valuable insights into Opthea's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Opthea is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Opthea operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Things to note about Opthea performance evaluation
Checking the ongoing alerts about Opthea for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Opthea help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Opthea is not yet fully synchronised with the market data | |
| Opthea has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 124.67 K. Reported Net Loss for the year was (220.24 M) with profit before taxes, overhead, and interest of 208.86 K. | |
| Opthea has about 44.63 M in cash with (161.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01. |
- Analyzing Opthea's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Opthea's stock is overvalued or undervalued compared to its peers.
- Examining Opthea's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Opthea's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Opthea's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Opthea's stock. These opinions can provide insight into Opthea's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Opthea Stock
If you are still planning to invest in Opthea check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Opthea's history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |